Skip to main content
Top
Published in: Rheumatology International 12/2019

01-12-2019 | Systemic Lupus Erythematosus | Observational Research

Changing trends in mortality in systemic lupus erythematosus? An analysis of SLE inpatient mortality at University Hospital Coventry and Warwickshire NHS Trust from 2007 to 2016

Authors: Himashi Anver, Shirish Dubey, James Fox

Published in: Rheumatology International | Issue 12/2019

Login to get access

Abstract

The aim of this study was to determine the causes of mortality in patients with systemic lupus erythematosus (SLE) at the University Hospital Coventry and Warwickshire (UHCW) NHS Trust over a 10 year period. This was a retrospective study of patients who had died in UHCW NHS Trust between 2007 and 2016, where SLE or lupus was mentioned on the death certificate. Ethics approval was obtained from the Research and Development. We identified 22 patients out of 1979 admissions with SLE who had died during the period between 2007 and 2016, 7 of these patients were under 50 years of age. The leading cause of death was infection with pneumococcus being associated with two deaths. Active disease was associated with younger age at death. Median age at death was 58.5 years, with median duration of disease of 14.5 years. Constitutional and mucocutaneous features were the most common items scoring on disease activity, seen in 68.2% and 45.45%, respectively. We identified three patients with biopsy proven lupus nephritis and one patient with CNS lupus. Surprisingly, none of the patients died because of vascular problems. The study suggests a changing trend in SLE mortality with none of the deaths in this cohort being due to cardiovascular or cerebrovascular disease. Infection continues to be the biggest reason for mortality in this cohort and greater emphasis is needed on vaccination for preventable infections like pneumococcus.
Literature
1.
go back to reference Bernatsky S, Bolvin JF, Joseph L et al (2006) Mortality in systemic lupus erythematosus. Arthritis Rheum 54(8):2550–2557CrossRef Bernatsky S, Bolvin JF, Joseph L et al (2006) Mortality in systemic lupus erythematosus. Arthritis Rheum 54(8):2550–2557CrossRef
2.
go back to reference Uramoto KM, Michet CJ, Thumboo J, Sunko J, O’Fallon WM, Gabriel SE (1999) Trends in the incidence and mortality of systemic lupus erythematosus, 1950–1992. Arthritis Rheum 42(1):46–50CrossRef Uramoto KM, Michet CJ, Thumboo J, Sunko J, O’Fallon WM, Gabriel SE (1999) Trends in the incidence and mortality of systemic lupus erythematosus, 1950–1992. Arthritis Rheum 42(1):46–50CrossRef
3.
go back to reference Jorge AM, Lu N, Zhang Y, Rai SK, Choi HK (2018) Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1994–2014). Rheumatology 57(2):337–344CrossRef Jorge AM, Lu N, Zhang Y, Rai SK, Choi HK (2018) Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1994–2014). Rheumatology 57(2):337–344CrossRef
4.
go back to reference Gordon C, Amissah-Arthur M-B, Gayed M et al (2018) The British Society of Rheumatology guidelines for the management of systemic lupus erythematosus in adults. Rheumatology 57(1):14–18CrossRef Gordon C, Amissah-Arthur M-B, Gayed M et al (2018) The British Society of Rheumatology guidelines for the management of systemic lupus erythematosus in adults. Rheumatology 57(1):14–18CrossRef
5.
go back to reference Chambers SA, Allen E, Rahman A, Isenberg D (2009) Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology 48(6):673–675CrossRef Chambers SA, Allen E, Rahman A, Isenberg D (2009) Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology 48(6):673–675CrossRef
6.
go back to reference Urowitz MB, Gladmann DD (1999) Evolving spectrum of mortality and morbidity in SLE (editorial). Lupus 8:253–255CrossRef Urowitz MB, Gladmann DD (1999) Evolving spectrum of mortality and morbidity in SLE (editorial). Lupus 8:253–255CrossRef
7.
go back to reference Yee CS, Su L, Toescu V, Hickman R, Situnayake D, Bowman S, Farewell V, Gordon C (2015) Birmingham SLE cohort: outcomes of a large inception cohort followed up for 21 years. Rheumatology 54(5):836–843CrossRef Yee CS, Su L, Toescu V, Hickman R, Situnayake D, Bowman S, Farewell V, Gordon C (2015) Birmingham SLE cohort: outcomes of a large inception cohort followed up for 21 years. Rheumatology 54(5):836–843CrossRef
8.
go back to reference Rees F, Doherty M, Grainge MJ, Lanyon P, Davenport G, Zhang W (2016) Mortality in systemic lupus erythematosus in the United Kingdom 1999-2012. Rheumatology 55(5):854–860CrossRef Rees F, Doherty M, Grainge MJ, Lanyon P, Davenport G, Zhang W (2016) Mortality in systemic lupus erythematosus in the United Kingdom 1999-2012. Rheumatology 55(5):854–860CrossRef
10.
go back to reference Kitas G, Nightingale P, Armitage J et al (2015) SAT0105 Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA). Ann Rheum Dis 74:688 Kitas G, Nightingale P, Armitage J et al (2015) SAT0105 Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA). Ann Rheum Dis 74:688
11.
go back to reference Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, Lockshin M, Merrill JT, Belmont HM, Askanase AD, McCune WJ, Hearth-Holmes M, Dooley MA, Von Feldt J, Friedman A, Tan M, Davis J, Cronin M, Diamond B, Mackay M, Sigler L, Fillius M, Rupel A, Licciardi F, Buyon JP (2005) Combined oral contracpetives in women with systemic lupus erythematosus. N Engl J Med 353(24):2550–2558CrossRef Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, Lockshin M, Merrill JT, Belmont HM, Askanase AD, McCune WJ, Hearth-Holmes M, Dooley MA, Von Feldt J, Friedman A, Tan M, Davis J, Cronin M, Diamond B, Mackay M, Sigler L, Fillius M, Rupel A, Licciardi F, Buyon JP (2005) Combined oral contracpetives in women with systemic lupus erythematosus. N Engl J Med 353(24):2550–2558CrossRef
12.
go back to reference Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, D’Cruz D, Griffiths B, Khamashta M, Maddison P, McHugh N, Snaith M, Teh LS, Yee CS, Zoma A, Gordon C, BILAG 2004 (2005) Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology 44(7):902–906. https://doi.org/10.1093/rheumatology/keh624 CrossRefPubMed Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, D’Cruz D, Griffiths B, Khamashta M, Maddison P, McHugh N, Snaith M, Teh LS, Yee CS, Zoma A, Gordon C, BILAG 2004 (2005) Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology 44(7):902–906. https://​doi.​org/​10.​1093/​rheumatology/​keh624 CrossRefPubMed
14.
go back to reference Gordon C (2002) Long-term complications of systemic lupus erythematosus. Rheumatology 41(10):1095–1100CrossRef Gordon C (2002) Long-term complications of systemic lupus erythematosus. Rheumatology 41(10):1095–1100CrossRef
15.
go back to reference Mosca M, Tani C, Aringer M et al (2010) European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 69(7):1269–1274CrossRef Mosca M, Tani C, Aringer M et al (2010) European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 69(7):1269–1274CrossRef
16.
go back to reference Nived O, Sturfelt G, Wollheim F (1985) Systemic lupus erythematosus and infection: a controlled and prospective study including an Epidemiological Group. Q J Med 55(218):271–287PubMed Nived O, Sturfelt G, Wollheim F (1985) Systemic lupus erythematosus and infection: a controlled and prospective study including an Epidemiological Group. Q J Med 55(218):271–287PubMed
17.
go back to reference Petri M, Genovese M (1992) Incidence of and risk factors for hospitalization in systemic lupus erythematosus: a prospective study of the Hopkins Lupus Cohort. J Rheumatol 19(10):1559–1565PubMed Petri M, Genovese M (1992) Incidence of and risk factors for hospitalization in systemic lupus erythematosus: a prospective study of the Hopkins Lupus Cohort. J Rheumatol 19(10):1559–1565PubMed
18.
go back to reference Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M, Cairns TD, Lightstone L (2013) Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 72(8):1280–1286CrossRef Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M, Cairns TD, Lightstone L (2013) Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 72(8):1280–1286CrossRef
19.
go back to reference Ho A, Barr SG, Magder LS et al (2001) A decrease in complement is associated with increased renal and haematological activity in patients with systemic lupus erythematosus. Arthritis Rheum 44(10):2350–2357CrossRef Ho A, Barr SG, Magder LS et al (2001) A decrease in complement is associated with increased renal and haematological activity in patients with systemic lupus erythematosus. Arthritis Rheum 44(10):2350–2357CrossRef
20.
go back to reference Manger K, Manger B, Repp R, Geisselbrecht M, Geiger A, Pfahlberg A, Harrer T, Kalden J (2002) Definition of causes for death, end stage renal disease and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 61(12):1065–1070CrossRef Manger K, Manger B, Repp R, Geisselbrecht M, Geiger A, Pfahlberg A, Harrer T, Kalden J (2002) Definition of causes for death, end stage renal disease and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 61(12):1065–1070CrossRef
21.
go back to reference Kim WU, Min JK, Lee SH, Park SH, Cho CS, Kim HY (1999) Causes of death in Korean patients with systemic lupus erythematosus: a single centre retrospective study. Clin Exp Rheumatol 17(5):539–545PubMed Kim WU, Min JK, Lee SH, Park SH, Cho CS, Kim HY (1999) Causes of death in Korean patients with systemic lupus erythematosus: a single centre retrospective study. Clin Exp Rheumatol 17(5):539–545PubMed
22.
go back to reference Mok CC, Lee KW, Ho CT, Lau CS, Wong RW (2000) A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford) 39(4):399–406CrossRef Mok CC, Lee KW, Ho CT, Lau CS, Wong RW (2000) A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford) 39(4):399–406CrossRef
23.
go back to reference Moss KE, Ioannou Y, Sultan SM, Haq I, Isenberg D (2002) Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 61(5):409–413CrossRef Moss KE, Ioannou Y, Sultan SM, Haq I, Isenberg D (2002) Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 61(5):409–413CrossRef
29.
go back to reference Cervera R, Khamashta MA, Font J et al (1993) Systemic lupus erythematosus: clinical and immunological patterns of disease expression in a cohort of 1000 patients. Medicine (Baltimore) 72(2):113–124CrossRef Cervera R, Khamashta MA, Font J et al (1993) Systemic lupus erythematosus: clinical and immunological patterns of disease expression in a cohort of 1000 patients. Medicine (Baltimore) 72(2):113–124CrossRef
30.
go back to reference Praprotnik S, Bozic B, Kveder T, Rozman B (1999) Fluctuation of anti-Ro/SS antibody levels in patients with systemic lupus erythematosus and sjogren’s syndrome: a prospective study. Clin Exp Rheumatol 17(1):63–68PubMed Praprotnik S, Bozic B, Kveder T, Rozman B (1999) Fluctuation of anti-Ro/SS antibody levels in patients with systemic lupus erythematosus and sjogren’s syndrome: a prospective study. Clin Exp Rheumatol 17(1):63–68PubMed
31.
go back to reference Kasitanon N, Magder LS, Petri M (2006) Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) 85(3):147–156CrossRef Kasitanon N, Magder LS, Petri M (2006) Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) 85(3):147–156CrossRef
32.
go back to reference Bosch X, Guilabert A, Pallarés L, Cervera R et al (2006) Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus 15:584–589CrossRef Bosch X, Guilabert A, Pallarés L, Cervera R et al (2006) Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus 15:584–589CrossRef
33.
go back to reference Jaconsen S, Petersen J, Ullman S et al (1999) Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus. Scand J Rheum 28:75–80CrossRef Jaconsen S, Petersen J, Ullman S et al (1999) Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus. Scand J Rheum 28:75–80CrossRef
34.
go back to reference Urowitz MB, Gladman DD (2000) How to improve mortality and morbidity in patients with systemic lupus erythematosus. Rheumatology 39(3):238–244CrossRef Urowitz MB, Gladman DD (2000) How to improve mortality and morbidity in patients with systemic lupus erythematosus. Rheumatology 39(3):238–244CrossRef
35.
go back to reference Abu-Shakra M, Novack V (2012) Mortality and multiple causes of death in systemic lupus erythematosus- role of the death certificate. J Rheumatol 39(3):458–460CrossRef Abu-Shakra M, Novack V (2012) Mortality and multiple causes of death in systemic lupus erythematosus- role of the death certificate. J Rheumatol 39(3):458–460CrossRef
Metadata
Title
Changing trends in mortality in systemic lupus erythematosus? An analysis of SLE inpatient mortality at University Hospital Coventry and Warwickshire NHS Trust from 2007 to 2016
Authors
Himashi Anver
Shirish Dubey
James Fox
Publication date
01-12-2019
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 12/2019
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-019-04450-1

Other articles of this Issue 12/2019

Rheumatology International 12/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.